Novartis' Deal For Avidity And Its Late-Stage Muscle Disease Assets Has Caveats

Novartis AG will acquire Avidity Biosciences, Inc. for $12B, aiming to strengthen its neuroscience franchise. Learn more ...
GlobalData on MSN

BridgeBio’s stock up as muscular dystrophy therapy meets Phase III endpoints

BridgeBio Pharma will seek US approval of its limb-girdle muscular dystrophy (LGMD) small molecule after the drug met its ...
Fierce Biotech

BridgeBio aces phase 3 rare disease test, clearing path to FDA

The biotech’s phase 3 delivered the hoped-for second biomarker hit, reporting an 82% decline in serum creatine kinase after ...
BMJ

Neutralisation of muscle tumour necrosis factor alpha does not attenuate exercise-induced muscle pain but does improve muscle strength in healthy male volunteers

Brain Function Research Unit, School of Physiology, University of the Witwatersrand, Johannesburg, South Africa L Loram, School of Physiology, University of the Witwatersrand, 7 York Road, Parktown, ...
JSTOR Daily

Expression of Elastin, Smooth Muscle Alpha-Actin, and c-Jun as a Function of the Embryonic Lineage of Vascular Smooth Muscle Cells

In the avian embryo, vascular smooth muscle cells (VSMC) in the aortic arch (elastic) arteries originate in the neural crest, whereas other VSMC develop from local mesoderm. These two lineages have ...